Marksans Pharma Ltd
NSE: MARKSANS BSE: 524404Pharma
Marksans Pharma Ltd (MARKSANS) is a Pharma company listed on NSE: MARKSANS | BSE: 524404. With a market cap of ₹9,829 Cr and ROCE of 18.6%, ROE of 14.4%, it operates in the Indian Pharma sector.
₹217
52W: ₹155 — ₹271
PE 39.8 · Book ₹33 · +558% vs bookMarket Cap₹9,829 Cr
Stock P/E39.8Price to Earnings
ROCE18.6%Return on Capital
ROE14.4%Return on Equity
Div. Yield0.38%Face Value ₹1
Strengths
- +Company is almost debt free.
- +Company has delivered good profit growth of 37.7% CAGR over last 5 years
- +Company has been maintaining a healthy dividend payout of 20.5%
Weaknesses
- −Company has a low return on equity of 12.4% over last 3 years.
- −Company has high debtors of 171 days.
Shareholding Pattern
Promoters43.87%
FIIs16.76%
DIIs6.57%
Public32.78%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% |
| FIIs | 18.59% | 21.31%▲2.7 | 21.95%▲0.6 | 22.19%▲0.2 | 19.89%▼2.3 | 16.92%▼3.0 | 8.13%▼8.8 | 16.76%▲8.6 |
| DIIs | 3.75% | 4.1%▲0.3 | 4.3%▲0.2 | 4.55%▲0.3 | 5.5%▲1.0 | 5.28%▼0.2 | 5.91%▲0.6 | 6.57%▲0.7 |
| Public | 33.77% | 30.7%▼3.1 | 29.88%▼0.8 | 29.37%▼0.5 | 30.74%▲1.4 | 33.93%▲3.2 | 42.08%▲8.1 | 32.78%▼9.3 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 205 | 241 | 225 | 255 | 309 | 312 | 299 | 320 | 320 | 340 |
| Expenses | 167 | 199 | 191 | 213 | 245 | 252 | 248 | 250 | 248 | 264 |
| Operating Profit | 37 | 42 | 34 | 41 | 63 | 60 | 52 | 70 | 72 | 75 |
| OPM % | 18% | 17% | 15% | 16% | 21% | 19% | 17% | 22% | 22% | 22% |
| Net Profit | 31 | 25 | 33 | 32 | 63 | 55 | 38 | 48 | 100 | 61 |
| EPS ₹ | 0.69 | 0.56 | 0.73 | 0.71 | 1.39 | 1.22 | 0.83 | 1.06 | 2.2 | 1.34 |
AI Insights
Revenue Trend
TTM revenue at ₹1,279Cr, up 8.9% YoY. OPM at 21%.
Debt Position
Borrowings at ₹11Cr. Debt-to-equity ratio: 0.01x. Healthy balance sheet.
Institutional Flow
DIIs: 6.57% (+2.92pp change). FIIs: 16.76% (+1.86pp change). Promoters hold 43.87%.
Margin & Efficiency
ROCE declining from 35% (Mar 2014) to 19% (Mar 2025). Working capital days: 145.
Valuation
PE 39.8x with 18.6% ROCE. Price is 558% above book value of ₹33. Dividend yield: 0.38%.
Recent Announcements
- Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results And To Consider Recommendation Of Dividend If Any, For The Financial Year Ended March 31, 2026 12 May - Board meeting on May 26, 2026 to approve FY26 results and consider dividend recommendation.
- Compliances-Certificate Under Reg. 74 (5) Of SEBI (DP) Regulations, 2018 9 Apr - Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 1 Apr - USFDA final approval for Benzonatate Capsules USP 100 mg and 200 mg (ANDA) on April 1, 2026.
- Closure of Trading Window 26 Mar
- Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Mar - Newspaper publication regarding opening of special window for re-lodgement of the transfer request for physical shares
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse